FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro

Anticancer Drugs. 1991 Jun;2(3):279-83. doi: 10.1097/00001813-199106000-00010.

Abstract

Cyclosporin A (CsA) and FK-506 have similar immunosuppressive activity profiles and cyclophilin-like intracellular targets. Since CsA can reverse the multidrug resistance of tumor cells showing P-glycoprotein-mediated drug efflux, the possible resistance-modulating activity of FK-506 was evaluated in vitro with multidrug-resistant P388 cells and their sensitive parental controls. Higher concentrations of FK-506 than CsA were needed to achieve a similar degree of chemosensitization, suggesting that FK-506 might interact less efficiently than CsA with the P-glycoprotein expressed in multidrug-resistant tumor cells. However, FK-506 was active on a broader range of concentrations than CsA, particularly because of direct cytostatic effects of CsA which appeared at concentrations only slightly higher than those required to show a significant resistance-modulating activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amiodarone / pharmacology
  • Animals
  • Antibiotics, Antineoplastic / pharmacology*
  • Cyclosporine / pharmacology
  • Doxorubicin / pharmacology
  • Drug Resistance
  • Leukemia P388 / drug therapy
  • Tacrolimus / pharmacology*
  • Tumor Cells, Cultured / drug effects*
  • Verapamil / pharmacology
  • Vincristine / pharmacology

Substances

  • Antibiotics, Antineoplastic
  • Vincristine
  • Doxorubicin
  • Cyclosporine
  • Verapamil
  • Amiodarone
  • Tacrolimus